What Else Can Semaglutide Treat Besides Weight Loss?

Semaglutide is FDA-approved in the United States for five broad uses: improving blood sugar in adults with type 2 diabetes ^[1][3], reducing the risk of major cardiovascular events ^[1][2][3], reducing the risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease ^[1], long-term weight management ^[2], and treating a serious form of fatty liver disease called MASH ^[2]. Which of these uses applies depends on the brand, because each brand carries its own approved indication list even though all contain the same molecule ^[1][2][3].

There are three FDA-approved semaglutide brands: Ozempic, an injection given once weekly, first approved in 2017 ^[1]; Wegovy, available as an injection and as tablets, also with an initial US approval date of 2017 ^[2]; and Rybelsus, an oral tablet taken once daily at 7 mg or 14 mg, first approved in 2019 as the first GLP-1 medicine in pill form ^[3]. Only Novo Nordisk manufactures FDA-approved semaglutide medicines ^[3][5].

What is Ozempic approved for?

The Ozempic label lists three indications, and weight loss is not one of them ^[1]. Ozempic is approved:

• as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ^[1]
• to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease ^[1]
• to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease ^[1]

The label’s dosing section describes a titration schedule: start at 0.25 mg once weekly, increase to 0.5 mg once weekly after 4 weeks, then to 1 mg and later 2 mg once weekly if more glycemic control is needed, with at least 4 weeks between each increase ^[1]. These are label instructions for prescribers, not a suggestion for any individual.

The approval history: Ozempic was initially approved in 2017 for blood sugar control, and in 2020 it gained the cardiovascular indication for adults with type 2 diabetes and known heart disease ^[5].

What is Wegovy approved for?

Wegovy injection carries three indications, and the Wegovy tablet carries one ^[2].

Wegovy injection, in combination with a reduced calorie diet and increased physical activity, is approved ^[2]:

• to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
• to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight who have at least one weight-related comorbid condition
• to treat noncirrhotic MASH (formerly called NASH) with moderate to advanced liver fibrosis, consistent with stages F2 to F3, in adults

Wegovy tablets are approved only to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight ^[2]. The tablet’s highlights section lists no weight-loss or MASH indication ^[2].

The usual recommended maintenance dosage of Wegovy injection is 2.4 mg once weekly, and available strengths include a 7.2 mg pen sold as Wegovy HD ^[2]. Wegovy tablets come in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths, started at 1.5 mg once daily for 30 days and titrated every 30 days ^[2]. The label states that concomitant use of Wegovy tablets or injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended ^[2].

The Wegovy indication list has been updated repeatedly: the label’s recent-changes section shows Indications and Usage revisions in August 2025 and December 2025 ^[2]. The approval timeline runs from 2021, when Wegovy was approved for weight management in adults, to 2022, when the indication expanded to children aged 12 and older, to 2024, when the cardiovascular risk-reduction indication was added ^[7].

What is Rybelsus approved for?

Rybelsus is the oral semaglutide tablet, taken once daily at 7 mg or 14 mg ^[3]. On October 17, 2025, Novo Nordisk announced FDA approval of a new Rybelsus indication: reducing the risk of major adverse cardiovascular events such as cardiovascular death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether or not they have had a prior cardiovascular event ^[3]. That covers both primary prevention (preventing a first event) and secondary prevention (preventing another event in people who have already had one) ^[3].

The approval is based on the SOUL trial, a phase 3b randomized, double-blind, placebo-controlled trial with 9,650 participants, initiated in 2019 with a mean follow-up of 4 years, testing oral semaglutide 14 mg against placebo on top of standard of care ^[3]. Major adverse cardiovascular events occurred in 579 of 4,825 participants (12.0%) in the semaglutide group and 668 of 4,825 (13.8%) in the placebo group, a hazard ratio of 0.86 (95% CI, 0.77–0.96; p=0.006) ^[3]. That works out to a 14% relative reduction in risk at 4 years, and a 2% absolute risk reduction at 3 years ^[3].

On safety, serious adverse events occurred in 47.9% of the oral semaglutide group versus 50.3% of the placebo group, while adverse events leading to permanent discontinuation occurred in 15.5% of the semaglutide group versus 11.6% of the placebo group, mainly gastrointestinal disorders, infections, or infestations ^[3]. Rybelsus is not known to be safe or effective in children ^[3].

Here is how the three brands compare on approved uses:

Approved use	Ozempic (injection)	Wegovy (injection)	Wegovy (tablets)	Rybelsus (tablets)
Type 2 diabetes blood sugar control	Yes [1]	No [2]	No [2]	Yes [3]
Cardiovascular risk reduction	Yes, adults with T2D and established CV disease [1]	Yes, adults with established CV disease and obesity or overweight [2]	Yes, adults with established CV disease and obesity or overweight [2]	Yes, adults with T2D at high risk [3]
Chronic kidney disease (with T2D)	Yes [1]	No [2]	No [2]	No [3]
Weight management	No [1]	Yes, ages 12 and older [2]	No [2]	No [3]
Noncirrhotic MASH, fibrosis F2–F3	No [1]	Yes, adults, accelerated approval [2]	No [2]	No [3]

Does semaglutide help kidney disease?

Yes, for one specific group. On January 28, 2025, the FDA approved Ozempic to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease ^[5]. Novo Nordisk positions Ozempic as the only GLP-1 receptor agonist with this kidney indication ^[5].

The approval rests on the FLOW trial, an international, randomized, double-blind, placebo-controlled phase 3b trial that enrolled 3,533 adults with type 2 diabetes and chronic kidney disease — 1,767 assigned to once-weekly semaglutide 1.0 mg and 1,766 to placebo — across 28 countries at roughly 400 sites, starting in 2019 ^[4][5]. To enter the trial, participants needed an eGFR of 50 to 75 mL per minute per 1.73 m² with a urinary albumin-to-creatinine ratio above 300 and below 5,000, or an eGFR of 25 to below 50 with a ratio above 100 and below 5,000 ^[4].

The trial was stopped early on the recommendation of an independent monitoring committee after it met prespecified efficacy criteria, with a median follow-up of 3.4 years ^[4][5]. The primary composite outcome — kidney failure, at least a 50% sustained drop in eGFR, or death from kidney-related or cardiovascular causes — occurred in 331 semaglutide participants versus 410 placebo participants: 24% lower risk, with a hazard ratio of 0.76 (95% CI, 0.66–0.88; p=0.0003), and a 4.9% absolute risk reduction at 3 years ^[4][5].

Secondary outcomes also favored semaglutide: cardiovascular death had a hazard ratio of 0.71 (95% CI, 0.56–0.89); death from any cause was 20% lower (HR 0.80, 95% CI, 0.67–0.95, p=0.01); and major cardiovascular events were 18% lower (HR 0.82, 95% CI, 0.68–0.98, p=0.029) ^[4]. The mean annual eGFR slope was less steep by 1.16 mL per minute per 1.73 m² per year in the semaglutide group (p<0.001), meaning kidney function declined more slowly ^[4]. Serious adverse events occurred in 49.6% of the semaglutide group versus 53.8% of the placebo group ^[4].

One important limit: every FLOW participant had type 2 diabetes ^[4]. The Ozempic kidney indication likewise applies only to adults with type 2 diabetes and chronic kidney disease ^[1]. There is no approved kidney indication for people without diabetes ^[1][4]. For context, chronic kidney disease affects about 37 million US adults, and roughly 40% of people with type 2 diabetes also have chronic kidney disease ^[5].

Is semaglutide approved for fatty liver disease (MASH)?

Yes. On August 15, 2025, the FDA granted accelerated approval to Wegovy 2.4 mg injection, in combination with a reduced calorie diet and increased physical activity, to treat adults with noncirrhotic MASH — metabolic dysfunction-associated steatohepatitis, formerly known as NASH — with moderate to advanced liver fibrosis, stages F2 to F3 ^[7][6]. Wegovy received breakthrough therapy designation for this use ^[6].

The approval is based on the week-72 interim analysis of the phase 3 ESSENCE trial, which included 800 participants: 534 on Wegovy and 266 on placebo, on top of lifestyle changes ^[6][7]. The results ^[6][7]:

Week-72 outcome	Wegovy	Placebo	Difference (95% CI)
MASH resolution without worsening fibrosis	63%	34%	29 (21–36)
Fibrosis improvement without worsening MASH	37%	22%	14 (8–21)
Both endpoints achieved	33%	16%	17 (10–23) [7]

A total of 83.5% of the semaglutide patients maintained the 2.4 mg target dose through week 72 ^[7].

The full ESSENCE trial randomized 1,197 participants 2:1 to semaglutide 2.4 mg or placebo and runs for 240 weeks in two parts ^[7]. Part 2, which is ongoing, tests whether the inflammation and scarring improvements seen after 72 weeks translate into decreases in death, liver transplant, and other liver-related events ^[6].

That matters because of how the approval was granted. Accelerated approval lets a therapy for a serious condition reach the market earlier based on a surrogate endpoint — here, liver biopsy histology — with additional data required afterward to confirm a clinically meaningful benefit ^[6]. The Wegovy label states plainly that continued approval for the MASH indication may be contingent on verification of clinical benefit in a confirmatory trial ^[2]. So the approval is proof that Wegovy improved liver inflammation and scarring on biopsy, not proof that it prevents death or transplant; that question is still being studied ^[6][7].

Cirrhosis is explicitly excluded: the indication covers noncirrhotic MASH only, and the approval announcement states the indication is for people with moderate to advanced fibrosis, but not with cirrhosis of the liver ^[7][2]. Wegovy’s use for MASH is not established in children under 18 ^[7].

MASH is common: approximately 6% of US adults, about 14.9 million people, have it ^[6], and roughly one in three people with overweight or obesity worldwide have MASH ^[7].

Is semaglutide approved for heart failure?

No. Heart failure does not appear in the indications section of the current US Wegovy prescribing information, and it does not appear in the Ozempic indications list either ^[2][1]. The approved uses listed for Rybelsus are blood sugar control and cardiovascular risk reduction in type 2 diabetes, not heart failure ^[3]. No semaglutide brand is FDA-approved to treat heart failure in the United States.

What about peripheral artery disease or leg pain when walking?

No. Peripheral artery disease does not appear in the current US Ozempic prescribing information’s indications ^[1], and it is not among the approved uses listed for Wegovy or Rybelsus ^[2][3]. There is no approved semaglutide indication for peripheral artery disease or for walking impairment related to it.

Is semaglutide approved for sleep apnea?

No. Obstructive sleep apnea does not appear in the Wegovy or Ozempic US prescribing information ^[2][1], and it is not among the approved uses listed for Rybelsus ^[3]. No semaglutide brand carries a sleep apnea indication in the United States.

Is semaglutide approved for Alzheimer’s disease?

No. No cognitive or dementia indication appears in the Ozempic or Wegovy US prescribing information ^[1][2], and none is listed among Rybelsus’s approved uses ^[3]. Alzheimer’s disease is not an approved use of any semaglutide brand in the United States.

Is semaglutide approved for knee osteoarthritis, PCOS, or other conditions in the news?

No. Conditions people often ask about — knee osteoarthritis, type 1 diabetes, alcohol use, PCOS, skin conditions, lung disease, weight regain after bariatric surgery, and weight management in children younger than 12 — do not appear as approved indications in the Ozempic, Wegovy, or Rybelsus labels ^[1][2][3]. None of these is an FDA-approved semaglutide use in the United States.

The Wegovy weight indication covers ages 12 and older only; the label states it is not known whether Wegovy is safe and effective for long-term weight loss in children under 12 ^[2][7].

Does semaglutide cause cancer?

Both major labels carry a boxed warning — the FDA’s strongest warning — about thyroid C-cell tumors. The Ozempic label states that in rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures ^[1]. The Wegovy label states that in rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures ^[2]. Both labels state it is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent findings has not been determined ^[1][2].

Because of this, semaglutide is contraindicated — meaning it must not be used — in people with a personal or family history of medullary thyroid carcinoma, and in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[1][2][3]. The Ozempic label also lists contraindication in patients with a serious hypersensitivity reaction to semaglutide or any of the excipients in Ozempic ^[1]; the Wegovy label lists known hypersensitivity to semaglutide or any of the excipients ^[2].

The Ozempic label adds that routine monitoring of serum calcitonin, or the use of thyroid ultrasound, is of uncertain value for early detection of medullary thyroid carcinoma in patients treated with Ozempic ^[1].

What warnings apply no matter which condition semaglutide is used for?

The Ozempic and Wegovy labels carry a consistent set of warnings across all approved uses ^[1][2]:

• Acute pancreatitis has been observed with GLP-1 receptor agonists, including Ozempic and Wegovy; the labels instruct discontinuation if pancreatitis is suspected ^[1][2].
• Acute gallbladder disease, including gallstones and cholecystitis, has occurred ^[1][2].
• Diabetic retinopathy complications have been reported in trials. The Ozempic label states this warning generally and says patients with a history of diabetic retinopathy should be monitored; the Wegovy label frames the same warning specifically for patients with type 2 diabetes ^[1][2].
• Hypoglycemia risk rises when semaglutide is combined with insulin or an insulin secretagogue ^[1][2].
• Acute kidney injury can result from volume depletion caused by vomiting or diarrhea ^[1][2].
• Severe gastrointestinal reactions have been reported; semaglutide is not recommended in patients with severe gastroparesis ^[1][2].
• Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported ^[1][2].
• Wegovy carries a heart rate increase warning, with monitoring at regular intervals ^[2].
• Pulmonary aspiration during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists undergoing elective procedures; patients should tell healthcare providers about planned surgeries ^[1][2].

The most common adverse reactions reported in at least 5% of Ozempic patients are nausea, vomiting, diarrhea, abdominal pain, and constipation ^[1]. Wegovy’s common-reaction list adds headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, gastroesophageal reflux disease, hair loss, and hypoglycemia in patients with type 2 diabetes ^[2].

A Suicidal Behavior and Ideation warning was removed from the Wegovy label in January 2026, per the label’s recent-changes section ^[2].

Semaglutide also delays gastric emptying, which may affect the absorption of oral medications taken at the same time ^[1][2]. On pregnancy planning, the labels differ in wording: the Ozempic label instructs discontinuing Ozempic in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide ^[1], while the Wegovy label instructs discontinuing Wegovy at least 2 months before a planned pregnancy for patients receiving it for cardiovascular risk reduction or weight reduction, or for MASH where the potential risk outweighs the potential benefit, because of semaglutide’s long half-life ^[2]. And pens must never be shared between patients, even if the needle is changed ^[1][2].

How do you match a brand to the condition you need treated?

Because each brand has its own indication list, the same molecule is approved for different conditions under different names ^[1][2][3]. Ozempic and Rybelsus are approved for type 2 diabetes populations; Wegovy is the brand carrying the weight-management and MASH indications ^[1][2][3]. The Wegovy label also states that concomitant use of its tablets or injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended ^[2].

One safety note applies regardless of brand: Novo Nordisk states that only it manufactures FDA-approved semaglutide medicines, and it warns about unlawful compounded and counterfeit versions of semaglutide ^[3].

What is and is not an approved semaglutide use today?

The full picture: approved semaglutide uses now span blood sugar control, cardiovascular risk reduction in two different populations, kidney protection in type 2 diabetes with chronic kidney disease, weight management, and MASH with F2–F3 fibrosis — and the list of things semaglutide is not approved for is just as important ^[1][2][3]. Heart failure, sleep apnea, peripheral artery disease, Alzheimer’s disease, and the various conditions under study are not on any US semaglutide label today ^[1][2][3]. Any decision about starting, stopping, or switching a semaglutide medicine belongs with a clinician who can match the approved indication, the warnings, and the contraindications — including the MTC and MEN 2 history check — to an individual situation ^[1][2][3].

Sources

1. Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use. Prescribing information.
2. Novo Nordisk. Wegovy (semaglutide) injection. Prescribing information.
3. PR Newswire. FDA approves Novo Nordisk’s oral semaglutide for cardiovascular risk reduction in adults with type 2 diabetes who are at high risk.
4. PubMed. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.
5. PR Newswire. FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. January 28, 2025.
6. US Food and Drug Administration. FDA approves treatment for serious liver disease known as ‘MASH’.
7. PR Newswire. Wegovy approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
8. New England Journal of Medicine. Semaglutide in patients with heart failure with preserved ejection fraction and obesity.
9. Fierce Pharma. Novo Nordisk pulls Wegovy HF submission, will resubmit in 2025. August 7, 2024.
10. American College of Cardiology. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes - STRIDE. March 29, 2025.
11. US Food and Drug Administration. FDA approves first medication for obstructive sleep apnea.
12. GlobeNewswire. Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer’s disease progression. November 24, 2025.
13. PubMed. Once-weekly semaglutide in persons with obesity and knee osteoarthritis.
14. NEJM Evidence. Semaglutide in adults with type 1 diabetes and obesity.
15. PubMed. GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. Annals of Oncology, August 2026.
16. Diabetes, Obesity and Metabolism. GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials. 2025.
17. European Respiratory Society. Weight loss injection semaglutide can reduce asthma attacks by up to 40 per cent. September 8, 2026.
18. Nature Medicine. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.
19. Novo Nordisk. STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification. September 7, 2026.
20. PubMed. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.